CagriSema: Weight Loss, Weekly Doses and Tirzepatide
Two appetite-related medicines, one investigational treatment
CagriSema combines cagrilintide and semaglutide for weight management. In REDEFINE 1, people lost about one fifth of their starting weight on average over 68 weeks. It is still investigational.
The trial product, dose and comparison matter. Combining separately sourced vials is not equivalent to receiving the product studied in these trials.
REDEFINE 1: average body-weight reduction at 68 weeks
- Cagrilintide + semaglutide
- 20.4 %
- Placebo
- 3 %
The studied dose and timeline
2.4 + 2.4 mg
Target dose
Cagrilintide plus semaglutide. The target was reached gradually, not used as the first dose.
Weekly
Under-skin injection
The trial included a 16-week dose-escalation period.
68 weeks
Treatment studied
Ongoing weight management, rather than a short cycle.
These are clinical-trial amounts, not an approved prescription schedule or instructions for combining research vials. Digestive side effects were common.
What Cagrisema is
Cagrilintide is a long-acting amylin analogue; semaglutide activates the GLP-1 receptor. The combination studies investigate whether two complementary appetite-related pathways improve outcomes beyond either component. CagriSema is not a synonym for cagrilintide and not evidence that any independently mixed vials reproduce the trial product.
One combination, two components
| Compare | Cagrilintide | Semaglutide |
|---|---|---|
| Drug family | Amylin analogue | GLP-1 receptor agonist |
| Place in CagriSema | Adds a second appetite-related pathway | Provides the GLP-1 component |
| Important distinction | Cagrilintide alone is not CagriSema | Semaglutide alone has separate approved products and instructions |
Trial results so far
REDEFINE 1 randomized 3,417 adults without diabetes who had obesity, or overweight with a related condition. The main published analysis counted treatment effects regardless of discontinuation or other weight-management treatment.
Why do other reports say 22.7%? That is a different analysis asking what would happen if participants adhered to treatment. It should not be substituted for the 20.4% treatment-policy result without explaining the assumption. The manufacturer’s trial summary identifies that distinction.
How does it compare with tirzepatide?
At the higher doses tested in REDEFINE 4, tirzepatide led to more average weight loss. This was an 84-week, open-label trial: people knew which medicine they received. The sponsor reported:
| Analysis | CagriSema 2.4/2.4 mg | Tirzepatide 15 mg |
|---|---|---|
| Assuming treatment adherence | 23.0% weight loss | 25.5% weight loss |
| Regardless of adherence | 20.2% weight loss | 23.6% weight loss |
CagriSema did not meet the trial’s primary noninferiority endpoint. These are sponsor-reported topline findings, with a different duration and design from REDEFINE 1. They do not mean every person responds better to tirzepatide. February 2026 announcement.
Why do some newer headlines favor CagriSema? September 2026 results came from a different trial: REIMAGINE 5 compared lower doses in adults with type 2 diabetes. Its adherence-based estimates were 12.4% loss with CagriSema 1.0/1.0 mg versus 9.1% with tirzepatide 5 mg at 60 weeks. That does not overturn the higher-dose obesity comparison. Sponsor announcement.
Side effects
Digestive adverse events were common in REDEFINE 1: 79.6% with the combination versus 39.9% with placebo. They included nausea, vomiting, diarrhea, constipation and abdominal pain, and were mainly transient and mild to moderate. Those are trial averages, not reassurance that an individual should push through persistent symptoms. Primary publication.
Approval and practical questions
Is CagriSema approved? Novo Nordisk’s September 30, 2026 update still describes it as investigational and says US and Canadian applications were submitted in December 2025. Submission is not approval, and projected decision dates are not availability promises. Current sponsor update.
Can I recreate it by combining products? The trials do not establish the compatibility, stability or equivalence of a homemade mixture. A shared ingredient name does not reproduce the development program’s product controls.
Can the plotter predict weight loss? No. The cagrilintide page concerns the model for that component. Concentration and weight change are different outcomes, and the effect of a combination cannot be obtained by adding two exposure curves.
Related compounds & model context
Article citations are linked in the text. Related catalog entries have separate model inputs and source notes, which may include unverified estimates. See our methodology for model assumptions and limitations.